Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-12-31

Study Completion Date

2012-11-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase II trial is studying the side effects of giving topical imiquimod together with Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) to see how well it works in treating patients with advanced breast cancer. Biological therapies, such as imiquimod, may stimulate the immune system to kill tumor cells. Drugs used in chemotherapy, such as Abraxane, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imiquimod together with Abraxane may kill more tumor cells.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer

NCT00110695

Breast Neoplasms

COMPLETED PHASE2

A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer

NCT00789581

Breast Cancer

COMPLETED PHASE3

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

NCT00785291

Estrogen Receptor Negative Estrogen Receptor Positive HER2/Neu Negative +6 more

COMPLETED PHASE3

Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer

NCT00079118

Breast Cancer

COMPLETED PHASE2

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

NCT02788981

Breast Cancer

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To evaluate the safety of chemoimmunotherapy with topical imiquimod and Abraxane in breast cancer patients with recurrent chest wall disease or cutaneous metastasis.

II. To evaluate the anti-tumor effects of chemoimmunotherapy with topical imiquimod and Abraxane in breast cancer patients with recurrent chest wall disease or cutaneous metastasis.

SECONDARY OBJECTIVES:

I. To examine whether treatment with chemoimmunotherapy consisting of topical imiquimod and Abraxane augments endogenous tumor specific immunity.

II. To assess the effect of chemoimmunotherapy on circulating transforming growth factor (TGF)-beta levels.

OUTLINE:

Patients receive Abraxane intravenously (IV) over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions once daily (QD) on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 1, 4, 8, and 12 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Male Breast Cancer Recurrent Breast Cancer Skin Metastases Stage IV Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment (biological therapy, chemo)

Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.

Group Type EXPERIMENTAL

imiquimod

Intervention Type DRUG

Given topically

Abraxane

Intervention Type DRUG

Given IV

laboratory biomarker analysis

Intervention Type OTHER

Correlative studies

RNA analysis

Intervention Type GENETIC

Correlative studies

immunoenzyme technique

Intervention Type OTHER

Correlative studies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

imiquimod

Given topically

Intervention Type DRUG

Abraxane

Given IV

Intervention Type DRUG

laboratory biomarker analysis

Correlative studies

Intervention Type OTHER

RNA analysis

Correlative studies

Intervention Type GENETIC

immunoenzyme technique

Correlative studies

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Aldara IMQ R 837 Albumin-Stabilized Nanoparticle Paclitaxel nab paclitaxel nab-paclitaxel nanoparticle albumin-bound paclitaxel Nanoparticle Paclitaxel paclitaxel albumin-stabilized nanoparticle formulation immunoenzyme techniques

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with advanced stage refractory breast cancer
* Progressive or relapsed disease following standard therapy with chemotherapy and/or surgery, and/or radiation
* Patients must have measurable (bi-dimensional) chest wall disease and/or cutaneous metastatic lesions
* Patients must be at least 7 days from last chemotherapy and 30 days from local radiotherapy and/or systemic steroids
* Patients on bisphosphonates, trastuzumab, lapatinib and/or hormonal therapy are eligible
* White blood cell count \>= 1000/ul
* Absolute neutrophil count (ANC) \>= 1200/ul
* Platelets \> 75,000/ul
* Serum creatinine =\< 2.0 mg/dL, a creatinine clearance \> 60 ml/min
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2 X upper limit normal (ULN)
* Total bilirubin \< 2 X ULN
* Patients must have a Performance Status Score (Eastern Cooperative Oncology Group \[ECOG\] Scale) =\< 2
* Patients must have recovered from major infections and/or surgical procedures and, in the opinion of the investigator, not have a significant active concurrent medical illness precluding protocol treatment
* Men and women of reproductive ability must agree to contraceptive use during the study and for 1 month after imiquimod/Abraxane treatment is discontinued

Exclusion Criteria

* Patients with prior allergic reaction to taxanes
* Patients with any clinically significant active autoimmune disease requiring active treatment with systemic steroids or other immunomodulators
* Pregnant or breast-feeding women
* Patients with peripheral neuropathy \>= Grade 2

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No